Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Perception of Olopatadine 0.2% in Allergic Conjunctivitis
NCT01272089Phase 4Completed
- Sponsor
- Alcon Inc.
- Start
- May 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc.. Started May 2011; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01272089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01272089.